Xemed collaborator Dregely selected as finalist for Young Investigator Award

Xemed has learned that the International Society of Magnetic Resonance in Medicine’s Committee on the Young Investigators’ Awards has selected Dr. Isabel Dregely, who is a Xemed collaborator and former University of New Hampshire doctoral student, as one of the finalists for their W.S. Moore Award in Clinical Science. She is invited to prepare both an oral and a poster presentation based on her work entitled “Hyperpolarized Xenon-129 Gas-Exchange Imaging of Lung Microstructure: Preliminary Results in Subjects with Obstructive Lung Disease.” The winner among the finalists will be determined on the basis of their manuscript, abstract, and presentations, and will be determined by the Committee during the upcoming meeting of the ISMRM, to be held in Montreal Canada on May 9, 2011.

ABOUT XEMED—We are a product-focused diagnostic drug company with broad expertise and IP in the field of hyperpolarized gases, partnering with clinical researchers and the pharmaceutical industry to advance pulmonary functional MRI through regulatory approval towards worldwide commercial availability.

At Xemed, our mission is to develop inhaled diagnostic agents that are capable of improving the standard of care of respiratory diseases. We will accomplish this by establishing hyperpolarized gas as a scientifically robust, clinically validated, FDA approved, and publically available diagnostic agent for magnetic resonance imaging of lung functional microstructure. We work to demonstrate effectiveness in two fields: 1) guiding clinical management of respiratory diseases, and 2) as a drug development tool to evaluate of the safety and efficacy of new therapies